News Releases

May 27, 2020
Synlogic Hosts First Virtual R&D Event
Live Webcast Scheduled to Begin at 12.30 pm ET Today CAMBRIDGE, Mass. , May 27, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) today will host its first Virtual R&D Event which will include presentations from members of the Synlogic executive team providing an in-depth review of Synlogic's Synthetic...
May 21, 2020
Synlogic to Host Virtual R&D Event
CAMBRIDGE, Mass. , May 21, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) announced today that the company will host a Virtual R&D Event at 12:30 pm ET on Wednesday, May 27th, 2020 . The event will provide an in-depth review of Synlogic's Synthetic Biotic platform and programs for the treatment of...
May 21, 2020
Synlogic Announces Termination of AbbVie Collaboration Agreement
CAMBRIDGE, Mass. , May 21, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the termination of its collaboration with AbbVie, a global, research-based biopharmaceutical...
May 8, 2020
Synlogic Reports First Quarter 2020 Financial Results and Provides Business Update
-Cash and investments of $114 million provide runway into 2022 - -Company will host virtual R&D event highlighting progress in its Synthetic Biotic platform and programs on Wednesday, May 27, 2020 - - Company will host a conference call at 8:00 am ET today - CAMBRIDGE, Mass....
May 4, 2020
Synlogic Announces First Quarter 2020 Conference Call and Webcast
CAMBRIDGE, Mass. , May 4, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2020 financial results before the market...
March 30, 2020
Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities
CAMBRIDGE, Mass. , March 30, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines called Synthetic Biotic ™  medicines, today provided an update on its business operations and expected...
March 12, 2020
Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
- Synlogic ended 2019 with approximately $127 million in cash and investments, which provides runway into 2022 - - Company will host a conference call at 5:00 pm ET today - CAMBRIDGE, Mass. , March 12, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic...
March 11, 2020
Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit
CAMBRIDGE, Mass. , March 11, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) announced today that Richard Riese , M.D., Ph.D., Synlogic's chief medical officer, will present at the Chardan Microbiome Medicines Summit at Noon ET on Monday, March 16 th , 2020. This is a virtual event....
March 5, 2020
Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast
CAMBRIDGE, Mass. , March 5, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its fourth quarter and full year 2019 financial results...
February 18, 2020
Synlogic Announces Participation in Upcoming Investor Conferences
CAMBRIDGE, Mass. , Feb. 18, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic's president and chief executive officer, will participate in the following upcoming investor conferences: 9th Annual SVB Leerink Global Healthcare Conference on...
January 30, 2020
Synlogic Appoints Dr. Michael Burgess to its Board of Directors
CAMBRIDGE, Mass. , Jan. 30, 2020 /PRNewswire/ --  Synlogic, Inc ., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Michael Burgess ,   M.B., Ch.B., Ph.D., president of research and...
January 9, 2020
Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs
– First subject treated in SYNB1891 immuno-oncology study, data from monotherapy arm expected in 2020 – – Expansion of pipeline with new preclinical programs in secondary hyperoxaluria and maple syrup urine disease (MSUD) – – Phase 2 clinical trial of solid formulation of SYNB1618 in patients with...
Displaying 49 - 60 of 156